RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Hutchison China MediTech (Chi-Med) reported its parent company, a division of Hong Kong conglomerate CK Hutchison, sold $288 million of its Chi-Med stake. The secondary offering placed 12 million ADSs at $24 each, upsized from 8.5 million ADSs originally planned. The placement will reduce Hutchison Healthcare Holdings’ share of Chi-Med to 51.2%, which will drop further to 49.8% if the underwriters choose to exercise an option for an additional 1.8 million ADSs. All of the funds will belong to the parent company. Chi-Med currently has a market capitalization of $3 billion.
Source: China Biotoday
